CA2540005A1 - Pulmonary disease treatment - Google Patents

Pulmonary disease treatment Download PDF

Info

Publication number
CA2540005A1
CA2540005A1 CA002540005A CA2540005A CA2540005A1 CA 2540005 A1 CA2540005 A1 CA 2540005A1 CA 002540005 A CA002540005 A CA 002540005A CA 2540005 A CA2540005 A CA 2540005A CA 2540005 A1 CA2540005 A1 CA 2540005A1
Authority
CA
Canada
Prior art keywords
particles
mometasone furoate
less
diameters
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002540005A
Other languages
English (en)
French (fr)
Inventor
Francis M. Cuss
Keith B. Nolop
Ulo A. Palm
Heribert W. Staudinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2540005A1 publication Critical patent/CA2540005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002540005A 2003-09-26 2004-09-24 Pulmonary disease treatment Abandoned CA2540005A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50646803P 2003-09-26 2003-09-26
US60/506,468 2003-09-26
US55159604P 2004-03-09 2004-03-09
US60/551,596 2004-03-09
PCT/US2004/031444 WO2005030220A1 (en) 2003-09-26 2004-09-24 Pulmonary disease treatment

Publications (1)

Publication Number Publication Date
CA2540005A1 true CA2540005A1 (en) 2005-04-07

Family

ID=34396317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002540005A Abandoned CA2540005A1 (en) 2003-09-26 2004-09-24 Pulmonary disease treatment

Country Status (6)

Country Link
US (3) US20050148563A1 (enExample)
EP (1) EP1667687A1 (enExample)
JP (1) JP2007506768A (enExample)
CA (1) CA2540005A1 (enExample)
MX (1) MXPA06003376A (enExample)
WO (1) WO2005030220A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148262A1 (en) * 2009-06-17 2010-12-23 Mark Rutenberg Treatment of acute pulmonary inflammation induced by cigarette smoking
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
EP0969816B1 (en) * 1997-03-20 2004-12-15 Schering Corporation Preparation of powder agglomerates
JP3676674B2 (ja) * 1997-10-09 2005-07-27 シェーリング コーポレイション 噴霧のためのモメタゾンフロエート懸濁液
SE9801368D0 (sv) * 1998-04-20 1998-04-20 Astra Ab New use
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases

Also Published As

Publication number Publication date
JP2007506768A (ja) 2007-03-22
US20110200647A1 (en) 2011-08-18
US20050148563A1 (en) 2005-07-07
EP1667687A1 (en) 2006-06-14
WO2005030220A1 (en) 2005-04-07
MXPA06003376A (es) 2006-06-08
US20080107609A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
KR100234864B1 (ko) 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
Nelson et al. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma
WO1994013271A1 (en) System for dispensing pharmaceutically active compounds
Hsieh et al. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients
US20040009963A1 (en) Use of salmeterol and fluticasone propionate combination
US20110200647A1 (en) Pulmonary disease treatment
Nayak et al. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study
Reichel et al. EXTRAFINE BECLOMETHASONE DIPROPIONATE BREATH‐ACTUATED INHALER (400 μG/DAY) VERSUS BUDESONIDE DRY POWDER INHALER (800 μG/DAY) IN ASTHMA
HK1038703A1 (zh) 糖皮質類固醇在制備治療輕度/早期copd(慢性阻塞性肺病)的藥物中的應用
Giuntini et al. Present state of the controversy about regular inhaled beta-agonists in asthma
JP5154732B2 (ja) 薬剤
Gibson et al. Drug delivery in asthma: a comparison of spacers with a jet nebuliser
Derom et al. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices
Grzelewska-Rzymowska et al. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma
Tatsis et al. Efficacy of beclomethasone dipropionate HFA 200 μg once daily in chronic obstructive pulmonary disease and bronchial asthma
CA2456721C (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
Escribano et al. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial
EP2054057B1 (en) Combination andolast/glucocorticoids
Yates et al. Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma
Ruff et al. Efficacy and safety of extrafine beclomethasone dipropionate aerosol therapy in children with asthma: A twelve-week placebo-controlled trial
MXPA00009981A (en) Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
CZ20003874A3 (cs) Použití glukokortikosteroidu k výrobě léčiva pro léčbu mírných/počátečních forem chronické obstrukční plicní choroby

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130521